Jabłońska B. Is endoscopic treatment a useful therapeutic option for esophageal gastrointestinal stromal tumors? World J Gastrointest Endosc 2025; 17(7): 107790 [DOI: 10.4253/wjge.v17.i7.107790]
Corresponding Author of This Article
Beata Jabłońska, MD, PhD, Adjunct Professor, Department of Digestive Tract Surgery, Medical University of Silesia, Medyków 14, Katowice 40-752, Poland. bjablonska@poczta.onet.pl
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Endosc. Jul 16, 2025; 17(7): 107790 Published online Jul 16, 2025. doi: 10.4253/wjge.v17.i7.107790
Is endoscopic treatment a useful therapeutic option for esophageal gastrointestinal stromal tumors?
Beata Jabłońska
Beata Jabłońska, Department of Digestive Tract Surgery, Medical University of Silesia, Katowice 40-752, Poland
Author contributions: Jabłońska B contributed to conceptualization, data curation, literature review, formal analysis, investigation, validation, writing and editing the manuscript.
Conflict-of-interest statement: No conflicts of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Beata Jabłońska, MD, PhD, Adjunct Professor, Department of Digestive Tract Surgery, Medical University of Silesia, Medyków 14, Katowice 40-752, Poland. bjablonska@poczta.onet.pl
Received: March 30, 2025 Revised: April 10, 2025 Accepted: May 7, 2025 Published online: July 16, 2025 Processing time: 102 Days and 19.1 Hours
Abstract
Decisions regarding the management of patients with esophageal gastrointestinal tumors (EGISTs) are very challenging, as there are still no clear guidelines on the treatment of these tumors due to their rarity. Surgery remains the standard treatment, but it is known that surgical procedures performed on the esophagus are related to a high risk of serious postoperative complications and impaired quality of life. Endoscopic resection is both safe and effective for patients with low-risk EGISTs. This article presents the current therapeutic options in patients with EGISTs, including both the endoscopic and surgical approach, and discusses the results, strengths and limitations of the recent article by Xu et al regarding the endoscopic treatment outcome of EGISTs.
Core Tip: Decisions regarding the management of patients with esophageal gastrointestinal tumors (EGISTs) are very challenging, as there are still no clear guidelines on the treatment of these tumors due to their rarity. Currently, surgery remains the mainstay treatment in patients with EGISTs. Recently, the endoscopic approach has been introduced as a less invasive, but safe and effective treatment option for low-risk EGISTs.
